喘息・重症喘息：疫学予測（～2033年）

当レポートでは、主要8市場（米国、フランス、ドイツ、イタリア、スペイン、英国、日本、中国）における喘息・重症喘息について調査分析し、危険因子や併存疾患、過去の疫学的動向に関する情報を提供しています。

目次

第1章 喘息・重症喘息：エグゼクティブサマリー

• カタリスト
• 関連レポート
• 今後のレポート

第2章 疫学

• 疾患の背景
• 危険因子と併存疾患
• 世界の過去の動向
• 主要8市場の予測手法
• 喘息・重症喘息の疫学的予測（2023年～33年）
  • 12ヶ月以内に診断された喘息の患者数
  • 12ヶ月以内に診断された喘息の患者数：年齢別
  • 12ヶ月以内に診断された喘息の患者数：性別
  • 生涯に診断された喘息の患者数
  • 生涯に診断された喘息の患者数：年齢別
  • 生涯に診断された喘息の患者数：性別
  • 12ヶ月以内に診断された重症喘息の患者数
  • 12ヶ月以内に診断された重症喘息の患者数：年齢別
  • 12ヶ月以内に診断された重症喘息の患者数：性別
  • 生涯に診断された重症喘息の患者数
  • 生涯に診断された重症喘息の患者数：年齢別
  • 生涯に診断された重症喘息の患者数：性別
  • 12ヶ月以内に診断された重症喘息の患者数：炎症サブタイプ別
  • 生涯に診断された重症喘息の患者数：炎症サブタイプ別
• 議論
  • 疫学的予測の考察
  • COVID-19の影響
  • 分析の限界
  • 分析の強み

第3章 付録

List of Tables

• Table 1: Summary of newly added data types
• Table 2: Summary of updated data types
• Table 3: Global Initiative for Asthma Treatment Stages
• Table 4: Risk factors and comorbidities for severe asthma
• Table 5: High-prescribing physicians surveyed, by country

List of Figures

• Figure 1: 8MM, 12-month diagnosed prevalent cases of asthma, both sexes, N, all ages, 2023 and 2033
• Figure 2: 8MM, lifetime diagnosed prevalent cases of asthma, both sexes, N, all ages, 2023 and 2033
• Figure 3: 8MM, 12-month diagnosed prevalent cases of severe asthma, both sexes, N, all ages, 2023 and 2033
• Figure 4: 8MM, lifetime diagnosed prevalent cases of severe asthma, both sexes, N, all ages, 2023 and 2033
• Figure 5: 8MM, 12-month diagnosed prevalence of asthma, both sexes, %, all ages, 2013-33
• Figure 6: 8MM, lifetime diagnosed prevalence of asthma, both sexes, %, all ages, 2013-33
• Figure 7: 8MM, 12-month diagnosed prevalence of severe asthma, both sexes, %, all ages, 2013-33
• Figure 8: 8MM, lifetime diagnosed prevalence of severe asthma, both sexes, %, all ages, 2013-33
• Figure 9: 8MM, sources used and not used to forecast the 12-month diagnosed prevalent cases of asthma
• Figure 10: 8MM, sources used to forecast the lifetime diagnosed prevalent cases of asthma
• Figure 11: 8MM, sources used and not used to forecast the 12-month diagnosed prevalent cases of severe asthma
• Figure 12: 8MM, sources used to forecast the lifetime diagnosed prevalent cases of severe asthma
• Figure 13: 8MM, 12-month diagnosed prevalent cases of asthma, N, both sexes, all ages, 2023
• Figure 14: 8MM, 12-month diagnosed prevalent cases of asthma by age, N, both sexes, 2023
• Figure 15: 8MM, 12-month diagnosed prevalent cases of asthma by sex, N, all ages, 2023
• Figure 16: 8MM, lifetime diagnosed prevalent cases of asthma, N, both sexes, all ages, 2023
• Figure 17: 8MM, lifetime diagnosed prevalent cases of asthma by age, N, both sexes, 2023
• Figure 18: 8MM, lifetime diagnosed prevalent cases of asthma by sex, N, all ages, 2023
• Figure 19: 8MM, 12-month diagnosed prevalent cases of severe asthma, N, both sexes, all ages, 2023
• Figure 20: 8MM, 12-month diagnosed prevalent cases of severe asthma by age, N, both sexes, 2023
• Figure 21: 8MM, 12-month diagnosed prevalent cases of asthma by sex, N, all ages, 2023
• Figure 22: 8MM, lifetime diagnosed prevalent cases of severe asthma, N, both sexes, all ages, 2023
• Figure 23: 8MM, lifetime diagnosed prevalent cases of severe asthma by age, N, both sexes, 2023
• Figure 24: 8MM, lifetime diagnosed prevalent cases of severe asthma by sex, N, all ages, 2023
• Figure 25: 8MM, 12-month diagnosed prevalent cases of severe asthma by inflammatory subtypes, N, both sexes, ages >=20 years, 2023
• Figure 26: 8MM, lifetime diagnosed prevalent cases of severe asthma by inflammatory subtypes, N, both sexes, ages >=20 years, 2023

Asthma is a common lung condition that is characterized by the narrowing and swelling of the airways of the lungs and the production of excess mucus (Mayo Clinic, 2024). Common symptoms of asthma include wheezing, breathlessness, chest tightness, and coughing at night or early in the morning (NHS, 2021; CDC, 2024). These symptoms may come and go for some people, but severe episodes of symptoms, or asthma attacks, can be life-threatening (Mayo Clinic, 2024). Asthma symptoms can be managed with regular medication (Mayo Clinic, 2024). Asthma can affect people of all ages, but usually develops in childhood. Sometimes, asthma can develop for the first time in adulthood (NHS, 2021). In 2018, the global burden of asthma was estimated to affect 339 million people. Globally, asthma is the 16th most common cause of years lived with disability (Global Asthma Network, 2022).

Severe asthma, as defined by the Global Initiative for Asthma (GINA), is a subset of difficult-to-treat asthma that remains uncontrolled despite adherence to maximum optimal high-dose inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA) treatment and management of contributory factors, or that worsens when high-dose treatment is decreased (Global Initiative for Asthma, 2023). The European Respiratory Society (ERS) and American Thoracic Society (ATS) have also defined severe asthma, although it is functionally the same as the GINA definition used for this report (Chung et al., 2014). Severe asthma is categorized into type 2 inflammation, which includes eosinophilic and allergic asthma, and non-type-2 inflammation, which includes neutrophilic asthma (American Lung Association, 2024). Treatments for these types of asthma differ. The GINA estimates that the worldwide prevalence of severe asthma among asthma patients is around 3.7%, based on a study from the Netherlands (Global Initiative for Asthma, 2023).

Scope

• The Asthma and Severe Asthma Epidemiology Report and Model provide an overview of the risk factors, comorbidities, and global trends of asthma and severe asthma in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).
• The report includes a 10-year epidemiological forecast for the 12-month and lifetime diagnosed prevalent cases of asthma and severe asthma, segmented by age (0 years up to 80 years older by 10-year age groups) and sex. The 12-month and lifetime diagnosed prevalent cases of severe asthma are further segmented by inflammatory subtype (atopic or allergic asthma, eosinophilic or neutrophilic).

Reasons to Buy

• The Asthma and Severe Asthma Epidemiology series will allow you to:
• Develop business strategies by understanding the trends shaping and driving the global asthma and severe asthma markets.
• Quantify patient populations in the global asthma and severe asthma markets to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for asthma and severe asthma therapeutics in each of the markets covered.
• Understand magnitude of the asthma and severe asthma population by age and sex and the severe asthma population by inflammatory subtype.

Table of Contents

Table of Contents

• About GlobalData

1 Asthma and Severe Asthma: Executive Summary

• 1.1 Catalyst
• 1.2 Related reports
• 1.3 Upcoming reports

2 Epidemiology

• 2.1 Disease background
• 2.2 Risk factors and comorbidities.
• 2.3 Global and historical trends
• 2.4 8MM forecast methodology.
  • 2.4.1 Sources
  • 2.4.2 Forecast assumptions and methods.
  • 2.4.3 Forecast assumptions and methods: 12-month diagnosed prevalent cases of asthma - 8MM.
  • 2.4.4 Forecast assumptions and methods: lifetime diagnosed prevalent cases of asthma - 8MM.
  • 2.4.5 Forecast assumptions and methods: 12-month diagnosed prevalent cases of severe asthma.
  • 2.4.6 Forecast assumptions and methods: lifetime diagnosed prevalent cases of severe asthma.
  • 2.4.7 Forecast assumptions and methods: 12-month diagnosed prevalent cases of severe asthma by inflammatory subtypes.
  • 2.4.8 Forecast assumptions and methods: lifetime diagnosed prevalent cases of severe asthma by inflammatory subtypes.
• 2.5 Epidemiological forecast for asthma and severe asthma (2023-33)
  • 2.5.1 12-month diagnosed prevalent cases of asthma
  • 2.5.2 Age-specific 12-month diagnosed prevalent cases of asthma.
  • 2.5.3 Sex-specific 12-month diagnosed prevalent cases of asthma
  • 2.5.4 Lifetime diagnosed prevalent cases of asthma
  • 2.5.5 Age-specific lifetime diagnosed prevalent cases of asthma.
  • 2.5.6 Sex-specific lifetime diagnosed prevalent cases of asthma
  • 2.5.7 12-month diagnosed prevalent cases of severe asthma
  • 2.5.8 Age-specific 12-month diagnosed prevalent cases of severe asthma
  • 2.5.9 Sex-specific 12-month diagnosed prevalent cases of severe asthma
  • 2.5.10 Lifetime diagnosed prevalent cases of severe asthma
  • 2.5.11 Age-specific lifetime diagnosed prevalent cases of severe asthma
  • 2.5.12 Sex-specific lifetime diagnosed prevalent cases of severe asthma
  • 2.5.13 12-month diagnosed prevalence of severe asthma by inflammatory subtypes
  • 2.5.14 Lifetime diagnosed prevalence of severe asthma by inflammatory subtypes
• 2.6 Discussion
  • 2.6.1 Epidemiological forecast insight
  • 2.6.2 COVID-19 impact
  • 2.6.3 Limitations of the analysis
  • 2.6.4 Strengths of the analysis

3 Appendix

• 3.1 Bibliography
• 3.2 Primary research - high prescriber survey
• 3.3 About the Authors
  • 3.3.1 Epidemiologist
  • 3.3.2 Reviewers
  • 3.3.3 Vice President of Disease Analysis and Intelligence
  • 3.3.4 Global Head and EVP of Healthcare Operations and Strategy
• Contact Us